Skip to main content
VulnerabilityPublished

CVE-2025-62575: Mirion Medical EC2 Software NMIS BioDose · Incorrect Permissions

Affects Mirion Medical EC2 Software NMIS BioDoseSource CVE Database V5

0

Not known to be exploited · CVSS 8.7 High.

Data as of 26 Oct 2026, 10:12 UTC

CVSS 4.0 base score
8.7High
How severe the flaw is on the 0–10 CVSS scale.
EPSS
0.4% chance of exploitation in 30 days – higher than 36% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:L/SC:N/SI:N/SA:N

Exploitation evidence

  1. Disclosed: evidence found.

    CVE published 2 Dec 2025

  2. Detectable: no evidence on record.

    No public nuclei template indexed

  3. Weaponised: no evidence on record.

    No public exploit code indexed in Metasploit or Exploit-DB

  4. Exploited in the wild: no evidence on record.

    Not in CISA KEV and no source reports exploitation

  5. Observed by OffSeq Mirage: no evidence on record.

    No attack traffic recorded by OffSeq Mirage sensors

A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 26 Oct 2026.

What to do

Affected software

ProductAffectedFixed in
Mirion Medical EC2 Software NMIS BioDoseAffected
  • =0
Fixed in–

AI-suggested

  1. Immediately audit and reduce the privileges of the 'nmdbuser' and any other SQL accounts created by the EC2 Software NMIS BioDose installation, removing the sysadmin role and assigning only the minimum necessary permissions.
  2. Implement network segmentation and firewall rules to restrict access to the SQL Server instance only to authorized application servers and administrators.
  3. Enable detailed logging and monitoring of SQL Server activities, focusing on the use of stored procedures and privilege escalations.
  4. Apply principle of least privilege in all database and application configurations, reviewing default settings during installation or upgrades.
  5. If available, apply vendor patches or updates addressing this vulnerability as soon as they are released; if no patches exist, consider compensating controls such as isolating the database server.
  6. Conduct regular vulnerability assessments and penetration testing focused on database security and privilege management.
  7. Train IT and security staff on secure configuration practices for Microsoft SQL Server and the specific application to prevent recurrence.
  8. Develop and test incident response plans for potential exploitation scenarios involving database compromise.

Description

CVE-2025-62575 is a high-severity vulnerability in Mirion Medical's EC2 Software NMIS BioDose, affecting versions up to V22.02. The issue arises because the SQL Server user account 'nmdbuser' and other created accounts are assigned the sysadmin role by default, granting excessive privileges. This misconfiguration allows remote attackers to execute arbitrary code via certain built-in stored procedures without requiring user interaction or high authentication levels. The vulnerability has a CVSS 4.0 score of 8.7, indicating a significant risk to confidentiality, integrity, and availability. Although no known exploits are currently reported in the wild, the ease of exploitation and critical access level make it a pressing concern. European healthcare and medical research organizations using this software are particularly at risk due to the sensitive nature of the data and regulatory requirements. Mitigation requires immediate privilege reduction for SQL accounts, strict access controls, and monitoring of database activities.

References

Community reviews

Loading reviews…